advertisement
Kuwayama Y 9
Showing records 1 to 9 | Display all abstracts from Kuwayama Y60077 Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study
Tanihara H
Acta Ophthalmologica 2015; 93: e254-e260
60737 Evaluation of Quality of Life in Japanese Glaucoma Patients and its Relationship With Visual Function
Takahashi GI; Otori Y
Journal of Glaucoma 2016; 25: e150-e156
60077 Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study
Inoue T
Acta Ophthalmologica 2015; 93: e254-e260
60737 Evaluation of Quality of Life in Japanese Glaucoma Patients and its Relationship With Visual Function
Urashima M
Journal of Glaucoma 2016; 25: e150-e156
60077 Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study
Yamamoto T; Kuwayama Y
Acta Ophthalmologica 2015; 93: e254-e260
60737 Evaluation of Quality of Life in Japanese Glaucoma Patients and its Relationship With Visual Function
Kuwayama Y
Journal of Glaucoma 2016; 25: e150-e156
60077 Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study
Abe H
Acta Ophthalmologica 2015; 93: e254-e260
60737 Evaluation of Quality of Life in Japanese Glaucoma Patients and its Relationship With Visual Function
Journal of Glaucoma 2016; 25: e150-e156
60077 Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study
Suganami H; Araie M;
Acta Ophthalmologica 2015; 93: e254-e260